400例早期乳腺癌化疗过程中贫血发生率及相关因素

Incidence and risk factors of anemia in 400 patients with early breast cancer treated by chemotherapy

目的:探讨早期乳腺癌患者化疗过程中贫血的发生率及相关因素。方法:对2009-2011年本院乳腺外科共400例接受含紫杉烷方案化疗的早期乳腺癌患者进行回顾性分析,统计化疗过程中贫血发生率,并进行单因素分析及多因素Logistic回归分析探讨贫血相关因素。结果:400例早期乳腺癌患者接受含紫杉烷方案化疗期间贫血发生率为72.2%;化疗过程中发生贫血的相关因素包括:化疗方案、化疗前Hb<135.0g/L、年龄>60岁、BMI≤25 kg/m2和乙肝。结论 :早期乳腺癌化疗过程中贫血发生率较高,可根据化疗方案、化疗前Hb水平、年龄、BMI及是否有乙肝识别贫血高危患者,预测贫血发生率。

Objective To explore the incidence and predictive factors of anemia induced by chemotherapy in early breast cancer patients. Methods 400 early breast cancer patients treated by taxane-based regimens from 2009 to 2011 in our hospital were analyzed to obtain the incidence of anemia. Univariate analysis and multivariate logistic regression analysis were used to search for risk factors linked to the occurrence of anemia. Results Incidence of anemia was 72.2% in early breast cancer patients undergoing chemotherapy. The occurrence of anemia was related to 5 risk factors： chemotherapy regiments, Hb at baseline 〈 135.0 g/L, age 〉 60 years old, BMI ≤ 25 kg/m2 and HBV antigen positive. Conclusion The anemia incidence during chemotherapy is high in early breast cancer patients. Such factors, as chemotherapy regiments, Hb at baseline, age, BMI and HBV antigen, should be taken into account in identifying high risk patients and prevent anemia.